Genentech Herceptin adds FISH test
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genentech's sBLA to add fluorescence in situ hybridization (FISH) testing to Herceptin (trastuzumab) labeling clears FDA Aug. 28. The approval also adds data showing that patients testing positive on FISH benefited from the HER-2 breast cancer treatment. "In a retrospective analysis, patients selected using FISH testing treated with Herceptin in addition to standard chemotherapy had a 30% decrease in the risk of death and a 56% decrease in the risk of disease progression compared to patients treated with chemotherapy alone," the company said. Labeling already listed immunohistochemistry (IHC) as a diagnostic method of detecting HER-2 positive patients. FDA's Oncologic Drugs Advisory Committee unanimously recommended inclusion of the PathVysion FISH assay in Herceptin labeling in December 2001. The sBLA was submitted in March 200
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.